The Baker Institute Center for Health and Biosciences, together with the Texas Heart Institute, hosted a panel discussion on Texas H.B. 810, or “Charlie’s Law,” which was passed in the 85th Texas Legislative Session. This new legislation expands the right-to-try laws in Texas, allowing patients with chronic and terminal illnesses access to experimental stem cell interventions. The panelists examined the scope and impact of Charlie’s Law on research and health care, and discussed how best to protect patients moving forward.
This event is part of a series launched in 2016 dedicated to educating the public on the important intersection of science, medicine and policy in stem cell research at the state and national levels. The inaugural event, “Stem Cell Tourism Near and Far: Achieving a Compromise for the Patient,” focused on unproven stem cell interventions and the associated risks, as well as clinical research.
Funding for this program was generously provided by a grant from the Hamman Foundation.
Follow @BakerInstitute on Twitter and join the conversation online with #BakerStemCell.
Introduction
James T. Willerson, M.D.
President Emeritus, Texas Heart Institute
Panelists
The Honorable Paul Bettencourt
Texas State Senator, District 7
The Honorable Garnet Coleman
Texas State Representative, District 147
The Honorable Tan Parker
Texas State Representative, District 63
Doris A. Taylor, Ph.D.
Director, Regenerative Medicine Research, Texas Heart® Institute
The Honorable Charles Schwertner, M.D.
Texas State Senator, District 5
The Honorable John Zerwas
Texas State Representative, District 28
Moderator
Kirstin R.W. Matthews, Ph.D.
Fellow in Science and Technology Policy, Baker Institute
